Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study - Takeaways - MDSpire

Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study

  • By

  • Jan Herden

  • Andreas Schwarte

  • Thorsten Werner

  • Uwe Behrendt

  • Axel Heidenreich

  • Lothar Weissbach

  • September 30, 2020

  • 0 min

Share

  • 1

    Active surveillance (AS) for localized prostate cancer shows a 10-year cancer-specific survival rate exceeding 98%, comparable to invasive treatments.

  • 2

    The HAROW study, conducted from 2008 to 2013, enrolled 468 patients in AS, highlighting its application in a community-based setting.

  • 3

    During a median follow-up of 7.7 years, 28 patients (8.5%) died, with no prostate cancer-specific deaths reported.

  • 4

    Metastasis developed in 7 patients (2.1%) after a median of 5.4 years, primarily among those with very-low and intermediate-risk tumors.

  • 5

    Of the AS cohort, 56.8% discontinued treatment for invasive options, mainly due to biopsy upgrades and PSA elevation.

Original Source(s)

Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study

  • by Jan Herden, Andreas Schwarte, Thorsten Werner, Uwe Behrendt, Axel Heidenreich, Lothar Weissbach

  • September 30, 2020

Related Content

One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer

Radiotherapy in metastatic bladder cancer

Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer